DBV Technologies | 销售



金融业
股票价格
USD
资产
USD 110.5M
现金及等价物
USD 69.84M
流动资产
USD 88.88M
流动负债
USD 49.49M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 52.85M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 851.9M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 11.65M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


销售 更改 日
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amarin USD 49.67M 23.07M 2025-09
BioCryst Pharmaceuticals USD -86.95M 204.03M 2024-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
DBV Technologies USD 2.77M 1.31M 2025-09
Esperion Therapeutics USD 51.63M 22.2M 2024-09
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Incyte USD 1.51B 140M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12


DBV Technologies 销售 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.